SpringWorks Therapeutics (SWTX) has agreed to be acquired by German technology firm Merck KGaA for $47 per share in cash, the companies said in a joint statement Monday.
The consideration represents about $3.9 billion in equity value, or $3.4 billion in enterprise value, for SprinWorks.
The deal is expected to close in H2, subject to regulatory approvals and customary closing conditions.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。